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Abstract 1 
Context 2 
EAU Non Muscle Invasive Bladder Cancer (NMIBC) Guidelines recommend all low and 3 
intermediate risk patients receive a single immediate instillation of chemotherapy after TURB, 4 
but its use remains controversial.  5 
Objective 6 
Identify which NMIBC patients benefit from a single immediate instillation. 7 
Evidence Acquisition 8 
A systematic review and individual patient data (IPD) meta-analysis of randomized trials 9 
comparing the efficacy of a single instillation after TURB to TURB alone in NMIBC patients was 10 
carried out. 11 
Evidence Synthesis 12 
13 eligible studies were identified. IPD were obtained for 11 studies randomizing 2278 eligible 13 
patients, 1161 to TURB and 1117 to a single instillation of epirubicin, mitomycin C, pirarubicin 14 
or thiotepa. 15 
1128 recurrences, 108 progressions and 460 deaths, 59 due to bladder cancer, occurred. A 16 
single instillation reduced the risk of recurrence by 35%, HR = 0.65, 95% CI: 0.58-0.74, p < 0.001 17 
and the 5 year recurrence rate from 58.8% to 44.8%. The instillation did not reduce recurrences 18 
in patients with a prior recurrence rate > 1 recurrence/year or in patients with an EORTC 19 
recurrence score ≥ 5.  20 
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The instillation did not prolong either the time to progression or death from bladder cancer, but 21 
resulted in an increase in the overall risk of death (HR = 1.26, 95% CI: 1.05 – 1.51, p = 0.015, 5 22 
year death rates 12.0% versus 11.2%), with the difference appearing in patients with an EORTC 23 
recurrence score ≥ 5. 24 
Conclusions 25 
A single immediate instillation reduced the risk of recurrence, except in patients with a prior 26 
recurrence rate > 1 recurrence/year or an EORTC recurrence score ≥ 5. It does not prolong 27 
either time to progression or death from bladder cancer. The instillation may be associated 28 
with an increase in the risk of death in patients at high risk of recurrence in whom the 29 
instillation is not effective or recommended. 30 
 31 
Patient Summary 32 
A single instillation of chemotherapy immediately after resection reduces the risk of recurrence 33 
in non-muscle invasive bladder cancer, however it should not be given to patients at high risk of 34 





1. Introduction 38 
In low and intermediate risk patients with non-muscle invasive bladder cancer (NMIBC), the 39 
EAU NMIBC Guidelines Panel recommends a single immediate instillation of chemotherapy 40 
after complete transurethral resection (TURB) [1]. This recommendation stems from a June 41 
2004 literature based meta-analysis of a single immediate postoperative instillation of 42 
chemotherapy. Analyzing data extracted from publications of 7 randomized controlled trials 43 
(RCTs), the meta-analysis concluded that a single instillation significantly reduced the risk of 44 
recurrence after TURB, odds ratio = 0.61, 95% CI: 0.49-0.75, p < 0.0001, number needed to treat 45 
= 8.5 [2]. The AUA also supports use of an immediate postoperative instillation in patients with 46 
small volume, low grade Ta tumors [3]. Despite these recommendations, an immediate 47 
instillation of chemotherapy is not universally used in day to day clinical practice [4-7]. 48 
Several RCTs assessing the efficacy of an immediate instillation have been published since the 49 
meta-analysis, some of which questioned its efficacy, especially in intermediate risk patients 50 
[8]. One review called for it to be abandoned [9]. 51 
One limitation of the meta-analysis was that it was not based on individual patient data so time 52 
to recurrence, prognostic factor and subgroup analyses could not be carried out to identify 53 
which patients benefit from the instillation. Likewise, two recent literature based meta-analyses 54 
could not adequately answer this question [10 – 11].  55 
To identify which patients benefit from an immediate instillation, a new systematic review and 56 
meta-analysis using individual patient data has been undertaken. 57 
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This project was prospectively defined in a protocol at https://db.tt/Q87Yvkk7. 58 
2. Evidence Acquisition 59 
2.1 Trial Eligibility Criteria 60 
All RCTs comparing a single immediate instillation of chemotherapy after TURB to TURB alone 61 
in patients with single or multiple, primary or recurrent stage pTaT1 urothelial carcinoma of the 62 
bladder were eligible. Carcinoma in situ and/or postoperative irrigation were not exclusion 63 
criteria. Trials allowing additional treatment prior to first recurrence were not eligible. 64 
2.2 Literature Search 65 
Medline, Embase, and Cochrane controlled trials databases and clinicaltrials.gov were searched 66 
for relevant studies. No time limitations were applied. The search was supplemented by hand 67 
searching EAU and AUA meetings abstracts from 2005 to 2013, reference lists, searches in 68 
Google and discussions with clinical experts. The literature search strategy was developed 69 
starting in July 2013 with the final search in November 2013 using the strategy in Online 70 
Appendix 1. 71 
2.3 Review of Studies Identified by the Literature Search 72 
Each abstract was reviewed by at least 2 independent reviewers (see Acknowledgements). A 73 
Study Eligibility Form was filled out for studies identified as potentially eligible or where 74 
eligibility was unclear. These studies were entered in an Excel database to keep track of their 75 
status and final disposition. Full publications were requested to allow a more detailed 76 
assessment by the reviewer. For AUA and EAU abstracts, a similar procedure was followed. 77 
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Studies proposed as being eligible or where eligibility was unclear or there was disagreement 78 
between reviewers were reviewed by at least one member of the Steering Committee to reach 79 
a decision. 80 
2.4 Data Collection and Quality Control 81 
Individual patient data on baseline characteristics, treatment, and outcome were requested for 82 
eligible studies using a pre-defined format (Online Appendix 2). 83 
Data of each study were analyzed separately and compared to those in the publication. Results 84 
were sent to the principal investigator for approval along with any discrepancies noted. 85 
2.5 Data Synthesis and Statistical Evaluation 86 
2.5.1 Outcome Measures 87 
The efficacy of a single immediate instillation of chemotherapy after TURB was compared to 88 
TURB alone with respect to: 89 
Primary outcome: time to first recurrence, histologically confirmed.  90 
Secondary outcomes: time to progression to muscle invasive disease, overall duration of 91 
survival, time to death due to bladder cancer 92 
2.5.2 Statistical Evaluation 93 
The primary analysis was carried out in all eligible patients with pTa or pT1 tumors. 94 
Confirmatory analyses in all randomized patients could not be done due to missing data for 95 
ineligible patients. 96 
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Ignoring recurrences after the first, the number needed to treat (NNT) to prevent one 97 
recurrence within 5 years was calculated in eligible patients and in all randomized patients 98 
assuming ineligible patients recurred within 5 years. 99 
For time to event comparisons, starting point was date of randomization. For patients who died 100 
prior to an event of interest, death from a cause other than bladder cancer was a competing 101 
risk and date of death was the date of the competing risk event. Patients without an event were 102 
censored at last date of follow up. 103 
Times to recurrence, progression and death due to bladder cancer were estimated by 104 
cumulative incidence functions taking death prior to an event as competing risk. 105 
Overall duration of survival was estimated by the Kaplan-Meier technique. Median duration of 106 
follow up was calculated in all patients based on censoring at time of event. 107 
Time to event distributions were compared using a Cox proportional hazards model stratified 108 
by study. The Fine-Gray test for competing risks was calculated as a sensitivity analysis. All tests 109 
were two sided using 0.05 significance level. 110 
Fixed effect meta-analysis Forest plots were used to visually assess heterogeneity along with 111 
Cochran’s Q chi-square test for heterogeneity and Higgins I2. Heterogeneity of treatment effect 112 
was tested in a Cox proportional hazards model using treatment by covariate interactions for 113 
variables in Figure 3. This included the 2006 EORTC risk scores for recurrence and progression 114 
[12] and the 2013 EAU risk group classification [1]. Subgroup analyses were carried out for 115 
factors where the interaction was significant at 0.05. 116 
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Exploratory non-randomized comparisons were carried out according to the chemotherapy, 117 
delay between TURB and immediate instillation, and use of post-operative irrigation. 118 
No studies or patients were excluded for quality reasons.   119 
3. Evidence Synthesis 120 
3.1 Literature Search Results 121 
2365 abstracts were identified by the literature search (Online Appendix 1). After deletion of 122 
duplicates, 1559 abstracts remained and divided among 6 reviewers so that each abstract was 123 
reviewed by two reviewers. They identified 171 abstracts for which the full text was reviewed. 124 
Abstracts of two potentially eligible but unpublished studies were identified [13,14]. Attempts 125 
to contact the authors of these studies were unsuccessful. One study was ineligible due to use 126 
of fulguration instead of TURBT [15]. In another, a subgroup of 19 patients was potentially 127 
eligible. Since there were no recurrences in these patients, they would have not contributed to 128 
the treatment comparisons and were not included [16]. Three other potentially eligible 129 
unpublished studies without abstracts identified in clinicaltrials.gov were reviewed: 130 
NCT01475266, NCT00003725 and NCT00445601. 131 
After review of 171 full texts, 13 RCTs published between 1985 and 2011 were eligible for 132 
inclusion [8, 17–31].  133 
44 studies identified from EAU and AUA meeting abstracts did not provide additional eligible 134 
studies.  135 
Further details are provided in the PRISMA flow diagram (Online Figure 1). 136 
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3.2 Eligible Studies 137 
Table 1 lists the 13 eligible studies. For 2 studies with 106 (4.4%) of the 2384 eligible patients, it 138 
was not possible to obtain individual patient data [30-31]. In these two studies and the two 139 
unpublished studies with abstracts [13-14], a single instillation reduced the recurrence rate as 140 
compared to TURB alone. 141 
3.3 Eligible Studies with Individual Patient Data 142 
Individual patient data were obtained for all 2278 eligible patients entered [8, 17-29].  143 
Four were single center [22,23,28,29] and seven were multicenter (1 multi-national), three with 144 
a central randomization [21,25,26] and four with envelopes or local randomization lists 145 
[8,18,20,27]. No studies were double blind. 146 
3.3.1 Study Characteristics 147 
As found in the original publications, 2278 (84.2%) of 2705 randomized patients were eligible: 148 
86% on control (TURB only) and 83% on a single instillation. The main reason of ineligibility was 149 
an inappropriate histology as patients were randomized and treated prior to pathological 150 
confirmation. 1161 (51.0%) were randomized to control and 1117 (49.0%) to a single 151 
instillation. In three studies, patients in the control group received an immediate instillation of 152 
sterile water or saline after TURB [21,27,28]. 153 
Median follow up was 6.0 years for recurrence and 9.0 years for survival (Table 1). 154 
3.3.2 Baseline characteristics 155 
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Table 2 provides the distribution of baseline characteristics. Median age was 64.0 years, 73.3% 156 
were male, 81.4% had primary tumors and 77.3% a single tumor. The median tumor size was 2 157 
cm and 18.2% had a tumor > 3 cm. 74.3% were pTa, 52.8% G1/LG, 6.6% G3/HG and 1 patient 158 
had CIS. Among the 1620 patients for whom the EORTC recurrence score could be calculated, 159 
609 (37.6%) had a score of 0, 789 (48.7%) a score of 1-4 and 222 (13.7%) a score of 5-11. In the 160 
1865 patients for whom the EORTC progression score could be calculated, 879 (47.1%) had a 161 
score of 0, 699 (37.5%) a score of 2-6 and 287 (15.3%) a score of 7-17.  162 
Baseline characteristics are well balanced in the treatment groups, except there are slightly 163 
more T1 patients, 24.7% versus 21.8%, and HG/G3 patients, 8.0% versus 5.3%, on immediate 164 
instillation. There are thus more patients at high risk of progression on a single instillation. 165 
Epirubicin was used in 5 studies, mitomycin C in 4, pirarubicin in 1 and thiotepa in 1. Time of 166 
instillation was available in 837 patients: 335 (40.0%) received the instillation within 2 hours, 167 
467 (55.8%) between 3 to 12 hours and 35 (4.2%) after 12 hours (Table 3). 168 
Post-operative irrigation (non-randomized) was used in 898 (56.4%) patients while 694 (43.6%) 169 
patients did not receive irrigation. (Online Table 1). 170 
3.3.3 Time to First Recurrence 171 
1128 (49.5%) of 2278 patients recurred: 475 (42.5%) allocated to a single instillation and 653 172 
(56.2%) to TURB (Table 4). Median tumor diameter at first recurrence was 3 mm in both groups 173 
(Online Table 2). 174 
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The difference in time to first recurrence between treatments is statistically significant in favor 175 
of immediate instillation, with a reduction of 35% in the relative risk of recurrence: HR = 0.65, 176 
95% CI: 0.58 – 0.74, p < 0.001. 5 year recurrence rates were 44.8% (95% CI: 41.6% – 48.0%) on a 177 
single instillation and 58.8% (95% CI: 55.7% – 61.9%) on TURB. Median times to first recurrence 178 
were 12 and 3 years, respectively (Figure 1). 179 
The NNT to prevent 1 recurrence within 5 years is 7 eligible patients, 95% CI: 5.5 – 10, and 10 180 
randomized patients, 95% CI: 7 - 15. 181 
Figure 2 shows the Forest Plot of time to first recurrence stratified by chemotherapy and study. 182 
There was significant heterogeneity between studies, p < 0.0001, I2 = 73.8. Immediate 183 
instillation was not effective in the thiotepa study, interaction test p = 0.002. Reductions in 184 
relative risks of recurrence were similar for the other 3 chemotherapies. Non randomized 185 
comparisons suggest better efficacy when the instillation is given within two hours after TURB. 186 
3.3.3.1 Effect of an Immediate Instillation according to Patient Characteristics 187 
In Figure 3, the test for interaction is significant only for the prior recurrence rate and EORTC 188 
Recurrence Risk Score. Recurrent patients with a prior recurrence rate > 1 recurrence per year 189 
(Online Figure 2) and patients with a recurrence score > 5 (Online Figure 3) did not benefit from 190 
the instillation. 191 
3.3.3.2 Post-Operative Irrigation 192 
In a non-randomized comparison of 1592 patients, post-operative irrigation reduced the risk of 193 
recurrence, both overall (HR = 0.69, 95% CI: 0.59, 0.88, p < 0.001) and in the two treatment 194 
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groups. Adjusting for the randomized treatment and EORTC Recurrence Risk Score, post-195 
operative irrigation reduced the relative risk of recurrence by 21%, HR = 0.79, 95% CI: 0.67 – 196 
0.93, p = 0.004. A single instillation reduced the risk of recurrence, both in patients receiving 197 
and not receiving post-operative irrigation. 198 
3.3.4 Time to Progression  199 
Time to progression data were available in 8 studies with 1765 patients. 108 patients (6.1%) 200 
progressed, 57 (6.6%) of 866 patients receiving a single instillation and 51 (5.7%) of 899 patients 201 
on TURB alone (Table 4). 202 
Figure 4 presents the time to progression by treatment. The difference was not statistically 203 
significant: HR = 1.21, 95% CI: 0.83 – 1.78, p = 0.32. Five year progression rates were 5.6% (95% 204 
CI: 3.8% – 7.4%) on a single instillation and 4.8% (95% CI: 3.2% – 6.5%) on TURB alone.  205 
Time to progression stratified by chemotherapy and study is provided in Online Figure 4, with 206 
no significant heterogeneity between studies, I2 = 13.7. Stratification by the EORTC Progression 207 
Risk Score yielded similar results: HR = 1.09, 95% CI: 0.74 – 1.60, p = 0.68, as did stratification by 208 
stage and grade. 209 
3.3.4.1 Effect of an Immediate Instillation according to Patient Characteristics 210 
No interactions were statistically significant for progression, although the same trends as for 211 
recurrence were seen. There was a suggestion of a higher risk of progression (HR = 1.60) on an 212 
immediate instillation in the 220 patients with an EORTC Recurrence Risk Score > 5 (Online 213 
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Figure 5), however instillation patients in this subgroup had a higher baseline EORTC 214 
Progression Score, 8.2 versus 7.8. 215 
3.3.5 Overall Duration of Survival 216 
Survival data were available in 7 studies with 1509 patients.  The duration of follow up was 217 
similar in the two treatment groups with median of 9.0 years on a single instillation and 8.9 218 
years on TURB.  460 (30.5%) deaths were reported, in 242 (32.8%) of 737 patients receiving a 219 
single instillation and 218 (28.2%) of 772 patients with TURB alone. 59 (3.9%) died due to 220 
bladder cancer, 75 (5.0%) due to another malignant disease, and 282 (18.7%) due to associated 221 
chronic disease (Table 4). 222 
The difference in survival is statistically significant in favor of no instillation with a relative 223 
increase of 26% in the risk of death on an immediate instillation: HR = 1.26, 95% CI: 1.05 – 1.51, 224 
p = 0.015 (Figure 5). 5 year survival rates were 88.0% (95% CI: 85.3% – 90.3%) with a single 225 
instillation and 88.8% (95% CI: 86.1% – 91.0%) on TURB, with the curves separating after 6 226 
years. Median survivals were 13.1 years and 14.9 years, respectively.  227 
Online Figure 6 shows the duration of survival stratified by study and chemotherapy, with no 228 
evidence of heterogeneity between studies, I2 = 0. Stratification by the EORTC Progression Risk 229 
Score yielded similar results: HR = 1.24, 95% CI: 1.02 – 1.50, p = 0.03, as did stratification by 230 
stage and grade. 231 
3.3.5.1 Effect of an Immediate Instillation according to Patient Characteristics 232 
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There was a suggestion of a shorter survival on an immediate instillation in recurrent patients, 233 
patients with an EORTC Recurrence Risk Score > 5 and EAU high risk patients. (Online Figure 7) 234 
3.3.6 Time to Death Due to Bladder Cancer 235 
59 (3.9%) patients died due to bladder cancer, 32 (4.3%) of 737 patients receiving a single 236 
instillation and 27 (3.5%) of 772 patients on TURB (Table 4).  237 
Figure 6 presents the time to death due to bladder cancer by treatment group. The difference 238 
was not statistically significant: HR = 1.31, 95% CI: 0.78 – 2.19, p = 0.31. 5 year bladder cancer 239 
death rates were 2.1% (95% CI: 1.0% – 3.3%) in patients receiving a single instillation and 2.0% 240 
(95% CI: 0.9% – 3.1%) on TURB. Online Figure 8 presents time to death due to bladder cancer 241 
stratified by chemotherapy and study, with medium heterogeneity between studies, I2 = 47.3. 242 
Stratification by EORTC Progression Risk Score yielded a slightly reduced hazard ratio: HR = 243 
1.13, 95% CI: 0.67 – 1.91, p = 0.65, as did stratification by stage and grade. 244 
3.3.6.1 Effect of an Immediate Instillation according to Patient Characteristics 245 
The number of deaths due to bladder cancer is small and no interactions in Online Figure 9 246 
were statistically significant, but similar trends were seen as for overall survival, with a 247 
suggestion of a shorter disease specific survival on a single instillation in patients with 248 
recurrence risk score > 5. 249 
3.3.7 Relationship between Cause of Death and EORTC Recurrence Risk Score 250 
Table 5 lists the cause of death by treatment group according to EORTC Recurrence Risk Score. 251 
In patients with Scores 0 and 1 – 4, the duration of survival and the distribution of the causes of 252 
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death were similar in the two treatment groups. Despite adjustment for an imbalance in tumor 253 
stage and grade, this exploratory analysis suggests that in patients with Recurrence Risk Score > 254 
5, more patients may have died on a single instillation, 65/106 (61.3%), than on TURB alone, 255 
44/102 (43.1%), with a higher percent of patients dying from malignant disease (bladder cancer 256 
or other) compared to patients not receiving an instillation, 35 (33.0%) versus 20 (19.6%). This 257 
was not a planned subgroup analysis and these differences could have occurred by chance. 258 
4. Conclusions 259 
The results of our IPD meta-analysis have clearly confirmed the efficacy of a single immediate 260 
instillation of chemotherapy. The scientific rationale and explanation for its efficacy is based on 261 
its anti-tumor effect in destroying tumors cells floating in the irrigation fluid and urine after 262 
TURB and on its ablative effect on residual tumor cells at the site of the resection and on small 263 
overlooked tumors [32,33]. 264 
A single immediate instillation was not effective in patients with a prior recurrence rate > 1 265 
recurrence per year and in patients with EORTC recurrence score > 5. This last subgroup was 266 
mainly composed of patients with multiple tumors (50.9%), tumors > 3 cm (69.8%) and T1 267 
tumors (75.7%).  268 
These results can help us make more precise recommendations for clinical practice. The 269 
decision to give an early instillation should be based on information available at time of TURB: 270 
the previous recurrence rate and the size and number of tumors. The definitive stage and grade 271 
is unknown at this time. From the weight of these parameters in the EORTC Recurrence Score 272 
[12], an early instillation is recommended in patients with: 273 
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1) single or multiple (up to 7 lesions) primary papillary tumor(s) smaller than 3 cm 274 
2) single primary papillary tumors larger than 3 cm 275 
3) single small recurrent papillary tumor with an interval of more than 1 year since the previous 276 
recurrence 277 
Patients with multiple tumors, at least one of which is > 3 cm, will have an EORTC Recurrence 278 
Score > 6. An immediate instillation is not recommended in these patients. 279 
Non-randomized comparisons suggest the instillation is more effective when given within two 280 
hours after TURB. Indirect comparisons could not detect any differences in efficacy between 281 
mitomycin C and epirubicin.  282 
Once the stage and grade are available, further treatment can be planned according to the risk 283 
stratification [1]. 284 
The benefit of an early instillation was most pronounced in low risk patients in whom no further 285 
treatment before recurrence is recommended.  286 
In intermediate risk patients, where the 5 year recurrence rate after a single instillation is nearly 287 
40%, the results support EAU guideline recommendations that a single instillation alone is 288 
insufficient and should be followed by further instillations [1]. A systematic review 289 
demonstrated the best results for schedules where an early instillation preceded further 290 
instillations of chemotherapy [34]. In high risk patients receiving BCG, the only study assessing a 291 
single instillation was inconclusive [35]. 292 
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Recurrences in low risk patients are usually low stage, low grade [36,37]. In this meta-analysis, 293 
recurrences were mostly small, median size 3 mm. Theoretically, small recurrences can be 294 
managed by office fulguration under local anesthesia without a significant burden to the 295 
patient [9,38,39]. There are, however, no prospective randomized comparisons of this 296 
procedure.  297 
This meta-analysis provides non-randomized evidence that use of post-operative irrigation also 298 
reduces recurrences. It may act by helping prevent implantation of circulating tumor cells at the 299 
site of resection. This confirms the results of a previously published abstract [40], but should be 300 
considered with caution as details about duration of irrigation are lacking and the type of fluid 301 
was not available in all patients. 302 
As can be expected from its mode of action, a single instillation did not have a positive effect on 303 
either the long-term progression or survival rates. It was surprising that a significant increase of 304 
26% in the overall risk of death was found in patients with the instillation. Despite adjustment 305 
for imbalances in tumor stage and grade, exploratory analyses suggest a single instillation may 306 
be associated with a shorter survival in patients at high risk of recurrence, i.e. with an EORTC 307 
recurrence risk score > 5. This subgroup, with only 222 (13.7%) of the 1620 patients for whom 308 
the score could be calculated, is precisely the subgroup of patients in which an immediate 309 
instillation is not effective or recommended. Patients with a high prior recurrence rate and risk 310 
of recurrence may be at higher risk of (unrecognized) perforation, which could contribute to 311 
their poor prognosis [41]. 312 
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Lamm et al [42] found that intravesical chemotherapy did not influence the long-term course of 313 
the disease and raised concerns that repeated intravesical chemotherapy might be 314 
carcinogenic, however the EORTC found no evidence of carcinogenicity in 3 studies with more 315 
than 1200 patients [43,44]. 316 
This is the first meta-analysis to study this question which is based on individual patient data 317 
with a relatively long follow up and identify patients who benefit or not from an immediate 318 
instillation. Nevertheless, there are a number of limitations in the interpretation of the data, 319 
especially the long-term results. No information was collected on further treatment after 320 
recurrence or progression or on the occurrence of distant metastases. Only 7 studies 321 
contributed to progression comparisons and 5 studies to survival comparisons, 3 with a median 322 
follow up of more than 10 years. Survival was not a formal endpoint in these studies and it is 323 
unknown to what extent the cause of death was based on autopsy evidence. 324 
Finally, no information on adverse events was collected. Although some severe complications 325 
after early instillation have been reported [45,46], their frequency is low if indications for their 326 
use are respected and proper safeguards followed. 327 
In summary, although a single immediate instillation of chemotherapy reduced the relative risk 328 
of recurrence by 35% and 5 year recurrence rate by 14%, it is not effective in patients with a 329 
prior recurrence rate > 1 recurrence per year or in patients with EORTC Recurrence Risk Score > 330 
5. It does not prolong either the time to progression or the time to death due to bladder 331 
cancer. Exploratory analyses suggest that the instillation may be associated with an increase in 332 
the risk of death in patients at high risk of recurrence in whom the instillation is not effective 333 
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and thus not recommended. The long-term survival differences may be biased by the treatment 334 
received after recurrence and thus may be chance findings. Non-randomized evidence indicates 335 
the use of post-operative irrigation may also reduce recurrences. 336 
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